CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab -paclitaxel ( nab -P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).

Citation

• Chiorean, E. G., Von Hoff, D. D., Ervin, T. J., Arena, F. P., Infante, J. R., Bathini, V. G., . . . Lu, B. (2013). CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab -paclitaxel ( nab -P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 31(15_suppl), 4058. doi:10.1200/jco.2013.31.15_suppl.4058

Digital Object Identifier (doi)

• 10.1200/jco.2013.31.15_suppl.4058

Web Of Science Accession Number

Start Page

• 4058

End Page

• 4058

Volume

• 31

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   Clingan, Phillip (external author)

Publication Date

• 2013

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Chiorean, E. G., Von Hoff, D. D., Ervin, T. J., Arena, F. P., Infante, J. R., Bathini, V. G., . . . Lu, B. (2013). CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab -paclitaxel ( nab -P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 31(15_suppl), 4058. doi:10.1200/jco.2013.31.15_suppl.4058

Digital Object Identifier (doi)

• 10.1200/jco.2013.31.15_suppl.4058

Web Of Science Accession Number

Start Page

• 4058

End Page

• 4058

Volume

• 31

Issue

• 15_suppl

Place Of Publication